Rockwell Medical, Inc. (NASDAQ:RMTI - Free Report) - Research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Rockwell Medical in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.03 for the year, up from their prior forecast of ($0.03). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Rockwell Medical's current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical's Q4 2024 earnings at $0.02 EPS, Q1 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.03) EPS.
A number of other brokerages have also weighed in on RMTI. RODMAN&RENSHAW raised Rockwell Medical to a "strong-buy" rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They issued a "buy" rating and a $5.00 price target on the stock. Finally, StockNews.com cut shares of Rockwell Medical from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st.
Check Out Our Latest Report on RMTI
Rockwell Medical Stock Performance
Shares of RMTI traded down $0.03 during trading hours on Wednesday, reaching $2.22. 505,052 shares of the company traded hands, compared to its average volume of 382,914. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $3.46 and a 200-day moving average price of $2.66. Rockwell Medical has a 12-month low of $1.16 and a 12-month high of $5.15. The stock has a market capitalization of $71.75 million, a P/E ratio of -45.00 and a beta of 1.50.
Institutional Trading of Rockwell Medical
A number of hedge funds have recently modified their holdings of RMTI. Barclays PLC purchased a new position in shares of Rockwell Medical during the 3rd quarter valued at approximately $90,000. XTX Topco Ltd increased its holdings in Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company's stock valued at $113,000 after buying an additional 8,922 shares in the last quarter. Jane Street Group LLC purchased a new position in Rockwell Medical in the third quarter valued at $534,000. State Street Corp raised its position in shares of Rockwell Medical by 21.5% in the third quarter. State Street Corp now owns 95,004 shares of the company's stock worth $377,000 after acquiring an additional 16,800 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of Rockwell Medical by 75.6% during the 3rd quarter. HighTower Advisors LLC now owns 57,413 shares of the company's stock worth $228,000 after acquiring an additional 24,715 shares in the last quarter. Hedge funds and other institutional investors own 23.31% of the company's stock.
Rockwell Medical Company Profile
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Featured Articles
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
